読み込み中
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
終値時点
$1.48
−$0.03 · -1.99%
時間外
$1.47
−$0.01 · -0.68%
10月13日 19:15 ET
日中の時刻はETです。市場データは遅延する場合があります。
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
日中レンジ
現在 $1.48
52週レンジ
現在 $1.48
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
40
割高
センチメント
40
弱気
リスク
70
高リスク
モメンタム
22
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
日中レンジ
現在 $1.48
52週レンジ
現在 $1.48
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 3759.2万 USD | 4183.8万 USD | 4371.7万 USD | 3791.6万 USD | 3298.4万 USD |
| 販売・一般管理 | 1381.6万 USD | 1103.9万 USD | 1204.6万 USD | 1307万 USD | 901.8万 USD |
| 営業費用 | 5140.8万 USD | 5287.7万 USD | 5576.3万 USD | 5098.6万 USD | 4200.2万 USD |
| 受取利息 | 467.8万 USD | 732万 USD | 651.9万 USD | 94.7万 USD | 2.6万 USD |
| 支払利息 | — | — | 96.4万 USD | — | — |
| 営業利益 | −5140.8万 USD | −5287.7万 USD | −5576.3万 USD | −5098.6万 USD | −4200.2万 USD |
| 純利益 | −4637.7万 USD | −4300.2万 USD | −4750.5万 USD | −4797.8万 USD | −3790.9万 USD |
会社概要が更新されました 2026年10月13日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$11.00
上昇余地（643.24%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2015年10月7日 | 1:4 | — | — |
発効済み 2015年10月7日
1:4
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI819.12万0.00%2.3兆 USD0.03%$381.32-0.07%
iShares Russell 2000 ETFIWM363.4万0.00%777.48億 USD0.19%$276.7-0.43%
Vanguard Extended Market ETFVXF302.91万0.00%954億 USD0.05%$232.54-0.42%
Vanguard Russell 2000 ETFVTWO148.21万0.01%180億 USD0.06%$111.77-0.45%
iShares Russell 2000 Value ETFIWN110.59万0.01%137.52億 USD0.24%$210.99-0.05%
iShares Biotechnology ETFIBB105.28万0.01%107.38億 USD0.44%$200.02-2.08%
Vanguard Health Care ETFVHT75.72万0.00%220億 USD0.09%$316.37-1.34%
Schwab U.S. Small-Cap ETFSCHA74.04万0.00%217.13億 USD0.03%$32.56-0.31%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Health Care ETFVHTSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
